Cargando…

Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

BACKGROUND: This systematic review and meta-analysis aimed to determine the efficacy of macitentan in patients with pulmonary hypertension (PH). METHODS: A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Jinlv, Wang, Guizuo, Han, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ubiquity Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607635/
https://www.ncbi.nlm.nih.gov/pubmed/37901601
http://dx.doi.org/10.5334/gh.1274
_version_ 1785127588339908608
author Qin, Jinlv
Wang, Guizuo
Han, Dong
author_facet Qin, Jinlv
Wang, Guizuo
Han, Dong
author_sort Qin, Jinlv
collection PubMed
description BACKGROUND: This systematic review and meta-analysis aimed to determine the efficacy of macitentan in patients with pulmonary hypertension (PH). METHODS: A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment of PH with macitentan, compared with placebo or blank, were reviewed. Studies were pooled to weighted mean differences (WMDs) and risk ratios (RRs), with 95% confidence intervals (CIs). RESULTS: Six RCTs (enrolling 1,003 participants) met the inclusion criteria. Macitentan showed significant effects on 6-min walk distance (6MWD) (WMD 12.06 m, 95% CI 2.12 to 21.99 m), pulmonary vascular resistance (PVR) (WMD –186.51 dyn·s/cm(–5), 95% CI –232.72 to –140.29 dyn·s/cm(–5)), mean pulmonary artery pressure (mPAP) (WMD –3.20 mmHg, 95% CI –5.93 to –0.47 mmHg), N-terminal pro-brain natriuretic peptide (NT-proBNP) (WMD –232.47 ng/L, 95% wCI –318.22 to –146.72 ng/L), and cardiac index (WMD 0.39 L/min/m(2), 95% CI 0.20 to 0.58 L/min/m(2)). CONCLUSION: Macitentan significantly improved 6MWD, PVR, mPAP, NT-proBNP, and cardiac index in patients with PH. Macitentan should be further validated in patients with PH.
format Online
Article
Text
id pubmed-10607635
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Ubiquity Press
record_format MEDLINE/PubMed
spelling pubmed-106076352023-10-28 Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Qin, Jinlv Wang, Guizuo Han, Dong Glob Heart Review BACKGROUND: This systematic review and meta-analysis aimed to determine the efficacy of macitentan in patients with pulmonary hypertension (PH). METHODS: A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment of PH with macitentan, compared with placebo or blank, were reviewed. Studies were pooled to weighted mean differences (WMDs) and risk ratios (RRs), with 95% confidence intervals (CIs). RESULTS: Six RCTs (enrolling 1,003 participants) met the inclusion criteria. Macitentan showed significant effects on 6-min walk distance (6MWD) (WMD 12.06 m, 95% CI 2.12 to 21.99 m), pulmonary vascular resistance (PVR) (WMD –186.51 dyn·s/cm(–5), 95% CI –232.72 to –140.29 dyn·s/cm(–5)), mean pulmonary artery pressure (mPAP) (WMD –3.20 mmHg, 95% CI –5.93 to –0.47 mmHg), N-terminal pro-brain natriuretic peptide (NT-proBNP) (WMD –232.47 ng/L, 95% wCI –318.22 to –146.72 ng/L), and cardiac index (WMD 0.39 L/min/m(2), 95% CI 0.20 to 0.58 L/min/m(2)). CONCLUSION: Macitentan significantly improved 6MWD, PVR, mPAP, NT-proBNP, and cardiac index in patients with PH. Macitentan should be further validated in patients with PH. Ubiquity Press 2023-10-26 /pmc/articles/PMC10607635/ /pubmed/37901601 http://dx.doi.org/10.5334/gh.1274 Text en Copyright: © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review
Qin, Jinlv
Wang, Guizuo
Han, Dong
Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_full Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_fullStr Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_full_unstemmed Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_short Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_sort benefits of macitentan in patients with pulmonary hypertension: a systematic review and meta-analysis of randomized controlled trials
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607635/
https://www.ncbi.nlm.nih.gov/pubmed/37901601
http://dx.doi.org/10.5334/gh.1274
work_keys_str_mv AT qinjinlv benefitsofmacitentaninpatientswithpulmonaryhypertensionasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT wangguizuo benefitsofmacitentaninpatientswithpulmonaryhypertensionasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT handong benefitsofmacitentaninpatientswithpulmonaryhypertensionasystematicreviewandmetaanalysisofrandomizedcontrolledtrials